Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2025-02-28 Board/Management Inform…
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Board/Management Information 2025
Board/Management Information Classification · 100% confidence The document text is titled 'Direktørskifte og organisationsændring i Pharma Equity Group A/S' (Change of Director and Organizational Change). The content explicitly details the appointment of a new CEO (Christian Henrik Tange) and the resignation of the current CEO (Thomas Kaas Selsø), along with the appointment of a new CEO for a subsidiary. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-02-28 Danish
Board/Management Information 2025
Board/Management Information Classification · 100% confidence The document is an official announcement dated February 28, 2025, detailing significant changes in the executive management structure of Pharma Equity Group A/S, specifically announcing a new CEO (Christian Henrik Tange) and the resignation of the current CEO (Thomas Kaas Selsø), along with a new CEO for a subsidiary. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2025-02-28 English
Board/Management Information 2025
Board/Management Information Classification · 100% confidence The document explicitly announces a 'Change of executive management and organizational change' within Pharma Equity Group A/S. It details the appointment of a new CEO (Christian Henrik Tange) and the resignation of the current CEO (Thomas Kaas Selsø), as well as the appointment of a new CEO for a subsidiary. This content directly matches the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2025-02-28 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a formal 'Company Announcement' dated October 23, 2024, detailing a specific corporate event: the subsidiary Reponex Pharmaceuticals A/S obtaining patent protection in Japan for a cancer treatment (RNX-051). This type of announcement, which details intellectual property milestones, market significance, and quotes management, is characteristic of a general regulatory disclosure or news release that doesn't fit the highly specific categories like 10-K, ER, or DIV. Since it is a specific, material announcement that is not a financial report, a management change, or a director's trade, it falls best under the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard disclosures, or potentially 'LTR' if it were about legal proceedings, but patent grants are usually treated as general corporate news/filings. Given the options, RNS is the most appropriate fallback for a material, non-financial, non-management announcement.
2024-10-23 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) dated October 23, 2024, detailing that Reponex Pharmaceuticals A/S has obtained patent protection in Japan for a cancer treatment (RNX-051). It discusses the significance of this patent milestone for future licensing negotiations and investment rationale. This type of announcement, which communicates a specific, material corporate event (patent grant) that is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), fits best under the general category for regulatory announcements or specific corporate actions. Since it is not a director's dealing (DIRS), dividend notice (DIV), capital change (CAP/SHA), or management change (MANG), and it is a specific regulatory update, it falls under the broad 'Regulatory Filings' (RNS) category, which serves as a fallback for material, non-standard announcements. Given the short length (3673 chars) and the nature of reporting a specific event rather than providing a comprehensive report, RNS is the most appropriate classification.
2024-10-23 Danish
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse nr. 29) from Pharma Equity Group regarding the granting of a patent in Japan for a subsidiary's cancer treatment. While it contains information about the patent, it is a standard regulatory announcement issued via a news wire service (GlobeNewswire). It does not fit into specific categories like financial reports, board changes, or dividend notices. As it is a general corporate update filed with the exchange, 'RNS' (Regulatory Filings) is the most appropriate classification.
2024-10-23 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.